Navigation Links
Lightlake Therapeutics to Present at 6th Annual LD MICRO Conference
Date:11/20/2013

LONDON, Nov. 20, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it is scheduled to present at LD MICRO's 6th Annual Conference on Wednesday, December 4th, 2013, at 8:30 AM PST / 11:30 AM EST. The three-day event will host more than 200 companies in the micro-cap space at the Luxe Sunset Boulevard Hotel in Los Angeles, California.

Dr. Roger Crystal, CEO of Lightlake, will be presenting to investors and be available for one-on-one meetings during the conference.

About Lightlake Therapeutics

Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. For more information please visit: http://www.lightlaketherapeutics.com

About LD MICRO

LD MICRO is a by-invitation-only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. LD MICRO concentrates on finding, researching and investing in companies that are overlooked by most institutional investors. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

Forward Looking Statement

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Media Contacts:
KCSA Strategic Communications
Anne Donohoe / Taylor McGrann
+1 212.896.1261 / +1 212.896.1253
adonohoe@kcsa.com / tmcgrann@kcsa.com

Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239
pcarlson@kcsa.com / jdver@kcsa.com

 


'/>"/>
SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
2. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
3. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
4. Prostate Cancer Therapeutics Market Worth $8.0 billion by 2019
5. Edison expands international bio-pharmaceutical presence with launch of coverage of Onconova Therapeutics
6. Cell Therapeutics to Host Conference Call Today, Friday, November 15, 2013, at 8:30 a.m. Eastern Time, to Discuss Pacritinib Partnership
7. Signum Dermalogix Receives $1.6M Phase II SBIR Grant for the Development of Novel Atopic Dermatitis Therapeutics
8. PTC Therapeutics Reports Third Quarter 2013 Financial and Corporate Results
9. Aratana Therapeutics Reports Third Quarter 2013 Financial Results
10. Levi & Korsinsky, LLP Launches Investigation of SAREPTA THERAPEUTICS, INC. for Possible Violations of Federal Securities Laws
11. Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... 5, 2017 Sapheneia and Scannerside received FDA ... DoseCheck is a third-party Vendor neutral CT product that ... allows compliance with current MITA standards. ... DoseCheck solution is specifically designed to provide CT operators, ... radiation doses over a predefined threshold. Scannerside Dose Check ...
(Date:9/1/2017)... PALMER, Mass. , Sept. 1, 2017 ... Complete HealthCare Solutions, Inc , highlights opportunities for growth ... Street Journal report that Marlin Equity is seeking a ... is an annual award-winning 22-year-old healthcare solutions Value Added ... market.  "As the ...
(Date:8/29/2017)... , Aug. 29, 2017 In a ... security, and regulatory compliance for veterinary practices of all ... a new partnership that makes TITAN,s expertise in physical ... available to Cubex,s clients nationally. ... buying and handling controlled substances is at risk today," ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... 22, 2017 , ... Egg freezing and embryo freezing are ... a slight statistical advantage for live births, frozen eggs offer many advantages, depending ... undergoing medical treatment or who are concerned about the decline of their fertility ...
(Date:9/21/2017)... ... September 21, 2017 , ... 38-Year-Old Plastic Surgeon Gill at Aesthetic Surgery ... is pleased to announce that Plastic Surgeon Kiranjeet Gill has been awarded as one ... is an annual award that was started in 2003 to salute young achievers in ...
(Date:9/21/2017)... ... September 21, 2017 , ... The American Addiction ... Services for professionals in the addiction treatment industry entitled: Special Investigations Unit ... Insurance companies and state and federal governments are increasingly scrutinizing the addiction treatment ...
(Date:9/21/2017)... ... 21, 2017 , ... Demonstrating a consistent and continued commitment ... been awarded five-year accreditation status through the Public Health Accreditation Board ... by a PHAB-accredited health department now extend to more than 203 million people, ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, ... the life-sciences industry for ensuring label quality and improving patient safety. , ...
Breaking Medicine News(10 mins):